Skip To Main Content
Jason Rush on Muck Rack

Jason Rush

Southeast Asia
As seen in: BioRxiv, Cell Press, Recruiter.com, University of Tulsa, Clinical Leader, PseudoPod, mytowncolorado.com
Knowledge management for @ADB_HQ in S.E. Asia. Lead @ADBSEADS. Like—pro-poor development, @Broncos, single malt. Abhor—bigots, felons, science denial. Views=own

Get in touch with Jason

Contact Jason, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Human genetics guides the discovery of CARD9 inhibitors with anti-inflammatory activity

|
By Jason Rush, Steven Goldberg, Donald Raymond, Jeff Branson, Christopher Stratton, Aaron Patrick, Ruth A. Steele, Suraj Adhikary, Amanda Del Rosario, Annie Liu, Noah J. Gomersall, Michael H. Chung, Matthew J. Ranaghan, Xiebin Gu, Marta Brandt, Zhifang Cao, Adrian M. Bebenek, Kasper Hoebe, Daniel Graham, Jennifer Towne, Ramnik Xavier, Joshua D. Wertheimer, Mateusz Szuchnicki, Andrew J. Baltus, Blayne A. Oliver, Lawrence M. Szewczuk, Jennifer D. Venable
| Cell Press Verified
Keywords binder first signalosome innate immunity coiled coil drug discovery Crohn's disease fungal immunity small molecule inhibitor immune-mediated disease Get full text access Log in, subscribe or purchase for full access. References 1. Okada, Y. ∙ Wu, D. ∙ Trynka, G. ... Genetics of rheumatoid arthritis contributes to biology and drug discovery Nature. 2014; 506:376-381 2. Kurki, M.I. ∙ Karjalainen, J. ∙ Palta, P. ... FinnGen provides genetic insights from a well-phenotyped isolated population Nature.
Open in Who Shared Issue with article?

08.07.24 -- Another One For Ozempic? Investigator Recounts Trial For Chronic Kidney Disease

|
By Dan Schell Verified, Jason Rush, Emily Eldh
| Clinical Leader Verified
The release of the FDA’s guidance related to diversity in clinical trials details what trials need DAPs, what should be included, and how to submit them. Will this be the turning point that shifts the conversation surrounding diversity from marketing rhetoric to actual implementations? Join Clinical Leader Live on September 5th for a digital discussion on what is working now to improve the representation of age, sex, racial, and ethnic demographic characteristics in trials today.
Open in Who Shared Issue with article?

Identification of Small Molecule Inhibitors of PPM1D Using a Novel Drug Discovery Platform

|
By Wei Jiang, Jason Rush, Nancy Dumont, Subrata Shaw
| BioRxiv
Abstract Protein phosphatase, Mg2+/Mn2+ dependent 1D (PPM1D), is a serine/threonine phosphatase that is recurrently activated in cancer, regulates the DNA damage response (DDR), and suppresses the activation of p53. Consistent with its oncogenic properties, genetic loss or pharmacologic inhibition of PPM1D impairs tumor growth and sensitizes cancer cells to cytotoxic therapies in a wide range of preclinical models.
Open in Who Shared Issue with article?
See all 11 articles